The Chinese Actuarial Association is spearheading efforts to formulate net cost tables for commercial health insurance, aiming to implement the "Guiding Opinions on Promoting the High-Quality Development of Health Insurance" issued by the National Financial Regulatory Administration. This initiative is designed to build a comprehensive, multi-tiered commercial health insurance product system and enhance the alignment between premium rates and underwriting risks. The association has mobilized industry resources to undertake this critical task.
Progress is being made methodically in developing the net cost tables for commercial health insurance. The association has convened project teams comprising insurance companies to conduct experience analysis based on the industry's actual conditions, thereby advancing the compilation of these essential tables.
Concurrently, significant work is underway to calculate and analyze the costs of innovative pharmaceuticals. By establishing a regular communication mechanism with the pharmaceutical industry, the association aims to foster collaboration and information sharing. This effort involves gathering data on innovative drugs and strengthening cost calculation and analysis, which will support insurers in setting scientific and rational premiums, ultimately improving the match between insurance rates and risk exposure.
Furthermore, the association is steadily advancing the preparation of net cost tables for inclusive health insurance products, often referred to as "Hui Min Bao." This involves enhancing communication and coordination with external institutions to carry out cost calculation and analysis work in a stable and measured manner.
Looking ahead, the Chinese Actuarial Association will continue to intensify its analysis of commercial health insurance experience data. It will actively promote greater experience accumulation across the industry, further solidifying the foundation for sound operations and refined management. These efforts are expected to facilitate more scientific and rational pricing, optimize product offerings, and drive the high-quality development of the health insurance sector.
Comments